by Pranjal Mahna(CC BY-NC-ND 2.0)


This week the Mexican College of Medical Oncology put pressure on COFEPRIS due to the shortage of cancer drugs such as puritenol, cyclophosphamide and vincristine that has caused the suspension of therapies in public hospitals. Mexico undergoes an unequal vaccination campaign against chicken pox and PAHO reveals that the country does not have a national vaccination program. On the bright side, FEMSA continues its expansion in the pharmacy market with the purchase of GPF, a leading operator of pharmacies in Ecuador.

Mexico Health Review spoke with Juan Manuel Sotelo, Country Representant of PAHO/WHO on the improvements that could further advance Mexico’s health system and how to achieve universal access to healthcare.  Please, click here to read the interview.


Now jump into last’s week highlights:


  • Latin America has not been given the importance to provide varicella vaccinations and Mexico is waiting for resources to implement the national program that it needs, reported Carlos Espinal, Advisor for the Latin America region at the International Research and Development Center of Canada (IDRC) and malaria advisor for PAHO.
  • The Mexican multinational company, FEMSA, went a step further in its expansion in the pharmacy market. The company announced the purchase of GPF, a company with a history of 90 years and more than 620 points of sale in Ecuador.
  • The National Association of Manufacturers of Medicines (Anafam) revealed the shortage of oncological medicines in public institutions was due to an absolute dependence on the importation of chemical salts. The organization highlighted the crisis is not only affecting Mexico, but the crisis of cyclophosphamide is worldwide.


  • Disruption is imminent. Technology and current health systems are bending the healthcare curve toward personalized healthcare. The rise of technologies and increasing flow of information has allowed individuals to become more informed consumers of health care.
  • In Australia, the coalition between the pharmaceutical industry and a large number of lobbyist groups are allegedly creating an increase in the price of medicines of the country. Twenty-two of the 72 companies that engage lobbyists have made political donations in the past 19 years and donations peaked in the 2013-14 financial year, coinciding with the 2013 federal election.
  • Russia expects by the end of 2018 a high-point in the growth cycle of its medical device industry. The country is by far is the largest market in the Central and Eastern European region and the government attempts to bypass an import restriction on medical devices for public healthcare facilities.
  • The WHO reveals the excessive use of alcohol kills more than 3 million people each year and most of them are men. It represents 5 percent of the global disease burden.
Alessa Flores

by Alessa Flores

Industry Analyst and Journalist at Mexico Business Publishing

Share →

Leave a Reply

Your email address will not be published. Required fields are marked *